FDA allows Trimel to start CompleoTRT Phase III trial
CompleoTRT’s delivery technology is designed to provide patients with the therapeutic effect of supplementing testosterone levels while doing so with a small amount of drug in the form
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.
The current BAY 94-9343 program is directed against the target molecule mesothelin. BAY 94-9343, a HuCAL-derived antibody-drug conjugate, showed potent, targeted anticancer activity against mesothelin- expressing tumors in